Prostatic Neoplasms, Castration-Resistant

"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Descriptor ID	D064129
MeSH Number(s)	C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
Concept/Terms	Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Castration-Resistant Prostatic Neoplasm Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Prostatic Prostatic Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration Resistant Androgen-Insensitive Prostatic Neoplasms Androgen Insensitive Prostatic Neoplasms Androgen-Resistant Prostatic Neoplasms Androgen Resistant Prostatic Neoplasms Prostatic Neoplasms, Hormone Refractory Hormone Refractory Prostatic Neoplasms Prostatic Neoplasms, Androgen-Independent Androgen-Independent Prostatic Neoplasm Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen-Independent Prostatic Prostatic Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen Independent Prostatic Neoplasms, Androgen-Insensitive Androgen-Insensitive Prostatic Neoplasm Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen-Insensitive Prostatic Prostatic Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen Insensitive Prostatic Neoplasms, Androgen-Resistant Androgen-Resistant Prostatic Neoplasm Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen-Resistant Prostatic Prostatic Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen Resistant Androgen-Independent Prostatic Neoplasms Androgen Independent Prostatic Neoplasms Castration-Resistant Prostatic Neoplasms Castration Resistant Prostatic Neoplasms Prostatic Cancer, Castration-Resistant Prostatic Cancer, Castration-Resistant Cancer, Castration-Resistant Prostatic Cancers, Castration-Resistant Prostatic Castration-Resistant Prostatic Cancers Prostatic Cancer, Castration Resistant Prostatic Cancers, Castration-Resistant Androgen-Insensitive Prostatic Cancer Androgen Insensitive Prostatic Cancer Androgen-Resistant Prostatic Cancer Androgen Resistant Prostatic Cancer Prostatic Cancer, Hormone Refractory Hormone Refractory Prostatic Cancer Prostatic Cancer, Androgen-Independent Androgen-Independent Prostatic Cancers Cancer, Androgen-Independent Prostatic Cancers, Androgen-Independent Prostatic Prostatic Cancer, Androgen Independent Prostatic Cancers, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Androgen-Insensitive Prostatic Cancers Cancer, Androgen-Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Prostatic Cancer, Androgen Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Androgen-Resistant Prostatic Cancers Cancer, Androgen-Resistant Prostatic Cancers, Androgen-Resistant Prostatic Prostatic Cancer, Androgen Resistant Prostatic Cancers, Androgen-Resistant Androgen-Independent Prostatic Cancer Androgen Independent Prostatic Cancer Castration-Resistant Prostatic Cancer Castration Resistant Prostatic Cancer

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Prostatic Neoplasms, Castration-Resistant [C04.588.945.440.770.500]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Neoplasms, Castration-Resistant [C12.294.260.750.500]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Prostatic Neoplasms, Castration-Resistant [C12.294.565.625.500]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]
Prostatic Neoplasms, Castration-Resistant [C12.758.409.750.500]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms, Castration-Resistant".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.

Bar chart showing 15 publications over 9 distinct years, with a maximum of 4 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	1	0	1
2014	3	1	4
2015	2	0	2
2016	1	0	1
2017	1	0	1
2019	1	0	1
2021	2	1	3
2022	1	0	1
2023	1	0	1

Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.

Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59.

View in: PubMed
Shah YB, Shaver AL, Kelly WK, Lu-Yao G. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One. 2022; 17(8):e0273826.

View in: PubMed
Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021 Dec; 32(12):1365-1374.

View in: PubMed
Schiewer MJ, Knudsen KE. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urol Clin North Am. 2021 Aug; 48(3):339-347.

View in: PubMed
Chong W, Zhang Z, Luo R, Gu J, Lin J, Wei Q, Li B, Myers R, Lu-Yao G, Kelly WK, Wang C, Yang H. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. BMC Cancer. 2021 Jun 02; 21(1):655.

View in: PubMed
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019 07 30; 129(10):4492-4505.

View in: PubMed
Maher CM, Thomas JD, Haas DA, Longen CG, Oyer HM, Tong JY, Kim FJ. Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. Mol Cancer Res. 2018 02; 16(2):243-255.

View in: PubMed
Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699.

View in: PubMed
Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 01; 13:206.

View in: PubMed
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 2015 Feb 09; 27(2):223-39.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement